Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)